This paper measures the differences in access between patients who initiate treatment through their PBMs’ vertically integrated pharmacies, described here as affiliated pharmacies, compared to other non-affiliated pharmacies. We compare differences in access in both immunology and oral oncology markets, as patients affected by these conditions have previously been analyzed to show that despite the need for and efficacy of such medicines, utilization management tactics have delayed treatment.